Future Directions in EGFR-Mutated NSCLC: Data Needs and Evolving Pharmacist Roles

This discussion explores the evolving landscape of EGFR-mutated non–small cell lung cancer (NSCLC), focusing on both emerging clinical data and the future role of pharmacists in patient management. Panelists will identify key evidence gaps for therapies currently in use, including questions around long-term outcomes, sequencing strategies, resistance mechanisms, and comparative effectiveness across treatment modalities. The conversation will also consider how pharmacists’ roles may expand over the next five years, from overseeing therapy selection and managing adverse events to supporting adherence, facilitating patient education, and integrating real-world evidence into clinical decision-making. Emphasis will be placed on the pharmacist’s contribution to multidisciplinary care, optimizing safety, and improving patient-centered outcomes. Together, these insights underscore the importance of both robust data generation and an adaptive pharmacy workforce in shaping the future of EGFR-driven NSCLC management.